Brand Name(s): Bactroban, Centany
CAS nº: 12650-69-0
(myoo peer’ oh sin)

About Mupirocin

This new site is dedicated exclusively to mupirocin.

It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.

Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about mupirocin on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.

This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total mupirocin experience! 

Why is this medication prescribed?

Mupirocin, an antibiotic, is used to treat impetigo as well as other skin infections caused by bacteria.  It is not effective, however, against fungal or viral infections.

Unlike other antibiotics which act on either bacterial DNA or the cellular walls of bacteria, mupirocin blocks the activity of an enzyme called isoleucyl-tRNA synthetase within the bacteria. This enzyme is necessary in order for the bacteria to make proteins. Without the ability to make proteins, the bacteria dies.

See more Product Info

Latest News

Biofilms: Recent Study Supports Elimination of Biofilm Colonies; Sinus Patients may Benefit

Aerosol Science Laboratories (ASL Pharmacy) announces today a new formula for topical sinus use...

[more]

GSK Receives Approvable Letter for Topical Antibiotic, Altabax™ (retapamulin ointment), 1%

GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration has issued an...

[more]

Replidyne Commences Clinical Trials For REP8839

Replidyne, Inc. (Nasdaq: RDYN) announced today the initiation of Phase I clinical testing of its...

[more]

Replidyne enters clinical testing

Replidyne Inc. has initiated Phase I clinical testing of its topical anti-infective drug candidate...

[more]

New Topical Antibiotic May Inhibit Skin Infections in Humans

Researchers from Colorado have identified a new topical antibiotic that may inhibit skin infections...

[more]

This site is intended solely for U.S. audiences; products described here may be subject to different medical and/or regulatory requirements in other countries. This site is for educational purposes only; information contained within should not be used to diagnose or treat a health problem or disease. Please consult a licensed health care provider regarding your medical condition.The products mentioned are trademarks of their respective owners.